Kathryn Jean Wicht

Kathryn Jean Wicht

Auto-generated profile, based on publicly available information

Kathryn Jean Wicht

University of Cape Town

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
LRLeila S. Ross
Leila S. Ross
SDSatish K. Dhingra
Satish K. Dhingra
SMSachel Mok
Sachel Mok
TYTomas Yeo
Tomas Yeo
KWKathryn J. Wicht
Kathryn J. Wicht
DFDavid A. Fidock
David A. Fidock
The widely used antimalarial combination therapy dihydroartemisinin + piperaquine (DHA + PPQ) has failed in Cambodia. Here, we perform a genomic analysis that reveals a rapid increase in the prevalence of novel mutations in thePlasmodium falciparumchloroquine resistance transporter PfCRT following DHA + PPQ implementation. These mutations occur in parasites harboring the K13 C580Y artemisinin resistance marker. By introducing PfCRT mutations into sensitive Dd2 parasites or removing them from resistant Cambodian isolates, we show that the H97Y, F145I, M343L, or G353V mutations each confer resistance to PPQ, albeit with fitness costs for all but M343L. These mutations sensitize Dd2 parasites to chloroquine, amodiaquine, and quinine. In Dd2 parasites, multicopyplasmepsin 2, a candidate molecular marker, is not necessary for PPQ resistance. Distended digestive vacuoles were observed inpfcrt-edited Dd2 parasites but not in Cambodian isolates. Our findings provide compelling evidence that emerging mutations in PfCRT can serve as a molecular marker and mediator of PPQ resistance.

27 November 2019 in Nature
Verified
Journal Article
Closed access
PDF file
JKJonathan Kim
Jonathan Kim
YTYong Zi Tan
Yong Zi Tan
KWKathryn J. Wicht
Kathryn J. Wicht
SESatchal K. Erramilli
Satchal K. Erramilli
SDSatish K. Dhingra
Satish K. Dhingra
FMFilippo Mancia
Filippo Mancia

1 July 2020 in Cell Chemical Biology
Verified
Journal Article
Open access
MVManu Vanaerschot
Manu Vanaerschot
JMJames M. Murithi
James M. Murithi
Charisse Flerida PasajeCharisse Flerida Pasaje
Charisse Flerida Pasaje
SGSonja Ghidelli-Disse
Sonja Ghidelli-Disse
LDLouis Dwomoh
Louis Dwomoh
DFDavid A. Fidock
David A. Fidock
The search for antimalarial chemotypes with modes of action unrelated to existing drugs has intensified with the recent failure of first-line therapies across Southeast Asia. Here, we show that the trisubstituted imidazole MMV030084 potently inhibits hepatocyte invasion by Plasmodium sporozoites, merozoite egress from asexual blood stage schizonts, and male gamete exflagellation. Metabolomic, phosphoproteomic, and chemoproteomic studies, validated with conditional knockdown parasites, molecular docking, and recombinant kinase assays, identified cGMP-dependent protein kinase (PKG) as the primary target of MMV030084. PKG is known to play essential roles in Plasmodium invasion of and egress from host cells, matching MMV030084's activity profile. Resistance selections and gene editing identified tyrosine kinase-like protein 3 as a low-level resistance mediator for PKG inhibitors, while PKG itself never mutated under pressure. These studies highlight PKG as a resistance-refractory antimalarial target throughout the Plasmodium life cycle and promote MMV030084 as a promising Plasmodium PKG-targeting chemotype.

1 May 2014 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
NWNing Wang
Ning Wang
KWKathryn J. Wicht
Kathryn J. Wicht
KIKento Imai
Kento Imai
MWMing-Qi Wang
Ming-Qi Wang
TNTran Anh Ngoc
Tran Anh Ngoc
TITsutomu Inokuchi
Tsutomu Inokuchi

1 December 2014 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
RSRebecca D. Sandlin
Rebecca D. Sandlin
KFKim Y. Fong
Kim Y. Fong
KWKathryn J. Wicht
Kathryn J. Wicht
HCHolly M. Carrell
Holly M. Carrell
TETimothy J. Egan
Timothy J. Egan
David W. WrightDavid W. Wright
David W. Wright
The emergence of drug resistant strains of Plasmodium spp. creates a critical need for the development of novel antimalarials. Formation of hemozoin, a crystalline heme detoxification process vital to parasite survival serves as an important drug target. The quinoline antimalarials including chloroquine and amodiaquine owe their antimalarial activity to inhibition of hemozoin formation. Though in vivo formation of hemozoin occurs within the presence of neutral lipids, the lipophilic detergent NP-40 was previously shown to serve as a surrogate in the β-hematin (synthetic hemozoin) formation process. Consequently, an NP-40 mediated β-hematin formation assay was developed for use in high-throughput screening. Here, the assay was utilized to screen 144,330 compounds for the identification of inhibitors of crystallization, resulting in 530 hits. To establish the effectiveness of these target-based β-hematin inhibitors against Plasmodium falciparum, each hit was further tested in cultures of parasitized red blood cells. This effort revealed that 171 of the β-hematin inhibitors are also active against the parasite. Dose-response data identified 73 of these β-hematin inhibitors have IC50 values ⩽5 μM, including 25 compounds with nanomolar activity against P. falciparum. A scaffold-based analysis of this data identified 14 primary scaffolds that represent 46% of the 530 total hits. Representative compounds from each of the classes were further assessed for hemozoin inhibitory activity in P. falciparum infected human erythrocytes. Each of the hit compounds tested were found to be positive inhibitors, while a negative control did not perturb this biological pathway in culture.

1 June 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
WLWen-Jie Lu
Wen-Jie Lu
KWKathryn J. Wicht
Kathryn J. Wicht
LWLi Wang
Li Wang
KIKento Imai
Kento Imai
ZMZhen-Wu Mei
Zhen-Wu Mei
TITsutomu Inokuchi
Tsutomu Inokuchi